Leerink Partnrs Weighs in on Allakos FY2029 Earnings

Allakos Inc. (NASDAQ:ALLK) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Allakos in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Allakos’ current full-year earnings is ($1.16) per share.

Other equities research analysts also recently issued research reports about the stock. Citizens Jmp downgraded shares of Allakos from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 27th. Piper Sandler lowered Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $2.00.

Allakos Price Performance

Shares of ALLK opened at $0.28 on Thursday. The company has a 50-day moving average of $0.94 and a two-hundred day moving average of $0.87. The stock has a market cap of $24.92 million, a price-to-earnings ratio of -0.14 and a beta of 0.78. Allakos has a one year low of $0.23 and a one year high of $1.69.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock worth $3,508,000 after buying an additional 685,623 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Allakos by 8.9% during the third quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock worth $646,000 after acquiring an additional 80,763 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Allakos during the third quarter valued at $1,143,000. GSA Capital Partners LLP boosted its position in Allakos by 11.9% during the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Allakos in the second quarter valued at about $55,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.